Abstract
Background Deceased donor kidney allocation in the United States follows an objective algorithm that is designed to balance equity and utility. Organ procurement organizations (OPOs) are increasingly using out-of-sequence allocation of deceased donor kidneys (DDKs) to improve organ utilization rates. We investigated trends in the prevalence of out-of-sequence allocation in DDKs, and the association with successful organ placement, and its impact on equity and organ utilization.
Methods Using 2020-2023 transplant data from the Scientific Registry of Transplant Recipients and organ offer data from the potential transplant recipient dataset, we identified all organ offers for DDKs, including those placed out-of-sequence, along with donor and recipient characteristics. We obtained the prevalence of out-of-sequence allocation and placement in DDKs and assessed temporal trends across organ quality as measured by the kidney donor profile index (KDPI). Lorenz curves and Gini coefficients measured inequality for out-of-sequence transplantation at the transplant center and OPO levels.
Results From 2020 to 2023, out-of-sequence placement of DDKs increased from 340 kidneys in 2020 (2.3%) to 2,931 in 2023 (15.8%). Out-of-sequence placements now account for 1-in-7 DDK transplants and include kidneys across the organ quality spectrum, with 41% of these occurring with KDPI<50% (i.e., the highest quality) kidneys. By 2023, 91% of OPOs were using out-of-sequence allocation, reflected in the Gini coefficient decreasing from 0.89 to 0.47 with no appreciable impact on utilization rates.
Conclusions There has been a sharp increase in out-of-sequence allocation of DDKs including high-quality organs. Most of these kidneys are being placed at a small number of transplant centers, creating preferential access to transplantation and exacerbating inequities in access to transplantation.
Key Points
Out-of-sequence transplantation of deceased donor kidneys has increased dramatically from 2020 to 2023 without regard for organ quality.
A limited number of centers are responsible for a third of all out-of-sequence transplants, exacerbating inequality in access to transplants.
There has been no improvement in the utilization of deceased donor kidneys despite the increase of out-of-sequence placements.
Competing Interest Statement
S Mohan receives grant funding from the Kidney Transplant Collaborative and the NIH, and personal fees from Sanofi, Kidney International Reports, Specialist Direct and Health Services Advisory Group outside of the submitted work and is Chair of the UNOS Data Advisory Committee and Board Member for the Alliance for organ donation and transplantation. J.D. Schold reports consultancy for eGenesis and Sanofi Corporation; research funding from the Department of Defense, Gift of Life Foundation, Kidney Transplant Collaborative, NIH/NIDDK, and One Legacy Foundation; honoraria from eGenesis and Sanofi Inc.; advisory or leadership roles as a member of the Data Safety Monitoring Board for Bristol Myers Squibb and Chair of the UNOS Data Advisory Committee; and a speaker bureau for Sanofi. J Adler reports personal fees from Tegus outside of the submitted work. S.A. Husain reports being a member of the National Kidney Foundation Transplant Advisory Council.
Funding Statement
SAH is supported by NIDDK grant K23DK133729. SM is supported by DK116066, EB032910, DK126739, DK130058 and the Kidney Transplant Collaborative. DC is supported by the NIAID grant R25 AI 147393.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Columbia University Irving Medical Center institutional review board approved this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available by request from the Scientific Registry of Transplant Recipients (SRTR). Restrictions apply to the sharing of these data due to privacy or ethical restrictions.
